<DOC DOCNO="nw/wsj/01/wsj_0180@0180@wsj@nw@en@on">
<ENAMEX TYPE="ORG">Genetics Institute Inc.</ENAMEX> , <ENAMEX TYPE="GPE">Cambridge</ENAMEX> , <ENAMEX TYPE="GPE">Mass.</ENAMEX> , said it was awarded <ENAMEX TYPE="GPE">U.S.</ENAMEX> patents for Interleukin - 3 and bone morphogenetic protein .
The patent for Interleukin - 3 covers materials and methods used to make the human blood cell growth factor via recombinant DNA technology .
<ENAMEX TYPE="ORG">Sandoz Ltd.</ENAMEX> has licensed certain manufacturing and marketing rights for Interleukin - 3 from <ENAMEX TYPE="ORG">Genetics Institute</ENAMEX> and is conducting preclinical studies with it .
Interleukin - 3 may help in treating blood cell deficiencies associated with cancer treatment , bone marrow transplants and other blood - cell disorders , <ENAMEX TYPE="ORG">Genetics Institute</ENAMEX> said .
The <ENAMEX TYPE="ORDINAL">second</ENAMEX> patent describes bone morphogenetic protein - 1 , a substance that can induce formation of new cartilage .
The patent covers BMP - 1 type proteins and pharmaceutical compositions and methods for treating bone or cartilage defects , <ENAMEX TYPE="ORG">Genetics Institute</ENAMEX> said .
The company added that it has filed patent applications `` on a large number of different BMP proteins '' and the patent on BMP - 1 is the first it has received .
BMP products may be useful in fracture healing and in treating bone loss associated with periodontal disease and certain cancers , the company said .
</DOC>
